US2021323997A1PendingUtilityA1

C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

71
Assignee: VIIV HEALTHCARE UK NO 5 LTDPriority: Feb 4, 2016Filed: Jun 9, 2021Published: Oct 21, 2021
Est. expiryFeb 4, 2036(~9.5 yrs left)· nominal 20-yr term from priority
Inventors:Jie ChenYan ChenIra B. DickerRichard A. HartzNicholas A. MeanwellBeata Nowicka-SansAlicia Regueiro-RenSing-Yuen SitNy SinJacob SwidorskiBrian Lee Venables
A61P 31/18C12N 2740/16222C12N 9/506A61K 31/56C07J 63/008C07D 417/06C07C 2603/52C07D 401/06C07D 401/12C07J 53/002A61K 31/58
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:These compounds are useful for the treatment of HIV and AIDS.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . The compound 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2021323997A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.